Evidence-based treatment guidelines, including the Canadian Thoracic Society’s 2019 guideline, clearly define the place of triple inhaled therapy in the management of chronic obstructive pulmonary disease (COPD). However, clinicians may have inadequate knowledge about some aspects of COPD management, and may harbour misconceptions, including about the role of triple therapy versus dual inhaled therapy in COPD, treatment selection for COPD according to the patient, differences between various COPD inhaler devices, and the safety profiles of inhaled corticosteroids (ICS) used in COPD. This educational program discusses these aspects of triple therapy in COPD and addresses prevailing myths/misconceptions.
The program is composed of four vignettes:
- Vignette 1: Disease burden and approach to management
- Vignette 2: Triple therapy for COPD: the evidence
- Vignette 3: Selecting the right inhaler for the patient
- Vignette 4: ICS Risks and benefits in COPD
The vignettes cover available data and current recommendations for COPD management, and also include interactive patient case studies, to provide clinicians with a comprehensive update on this topic.